title: SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.
abstract: The interaction of the chemokine CXCL12 with CXCR4 regulates homing of tumoral cells in bone marrow in Waldenstrom macroglobulinemia (WM). We assessed the distribution and the clinical influence of the CXCL12 (-801GA) polymorphism using PCR RFLP in a series of 114 WM patients. CXCL12 (-801AA) genotype was more frequent in WM patients compared with control subjects (p = 0.01). On the other hand, CXCL12 (-801GG) patients had a shorter median survival after initiation of first line therapy than remaining patients (p = 0.01). In conclusion, the CXCL12 (-801GA) polymorphism may either be associated with a high incidence of WM or influence clinical outcome.
authors.affiliation: Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France. poulain-s@ch-valenciennes.fr
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Poulain
authors.forename: Marjan
authors.initials: M
authors.lastname: Ertault
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.forename: Valérie
authors.initials: V
authors.lastname: Coiteux
authors.forename: José
authors.initials: J
authors.lastname: Fernandes
authors.forename: Laure
authors.initials: L
authors.lastname: Stalnikiewicz
authors.forename: Patrick
authors.initials: P
authors.lastname: Duthilleul
authors.forename: Pierre
authors.initials: P
authors.lastname: Morel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000235:genetics*; D017931:DNA Primers; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D008258:Waldenstrom Macroglobulinemia / Q000235:genetics / Q000628:therapy*
chemical_list: D054377:Chemokine CXCL12; D017931:DNA Primers